GeneDx Holdings Corp. Ratios | P/E, ROE & Valuation

On the Key Ratios page for GeneDx Holdings Corp. (WGS), the latest P/E of -23.3 frames valuation, while ROE -38.72% and ROIC -14.69% indicates profitability and capital efficiency. Together with the current ratio of 3.30 and debt-to-equity 0.69, these signals help you judge whether valuation is supported by fundamentals across the historical rows.

Financial Performance Ratios

WGS Historical Per Share Metrics

7 years
Metric (FY)TTM202420232022202120202019
Revenue per Share$15.30$11.36$8.33$22.93$64.79$106.92$26.95
Net Income per Share$-3.58$-1.94$-7.23$-53.63$-74.93$-143.90$-4.08
Operating Cash Flow per Share$-1.64$-1.06$-7.41$-31.18$-58.15$-55.53$-2.57
Free Cash Flow per Share$-2.55$-1.26$-7.64$-32.58$-64.49$-74.59$-4.70
Cash per Share$4.46$5.25$5.35$12.11$122.31$64.48$0.00
Book Value per Share$8.22$9.12$9.38$24.78$118.50$-196.80$0.00
Tangible Book Value per Share$3.41$3.22$2.28$6.55$118.50$-196.80$0.00
Interest Debt per Share$5.73$4.43$4.93$7.85$4.22$28.32$0.00
CAPEX per Share$0.91$0.20$0.23$1.40$6.35$19.07$2.12

WGS Historical Valuation Ratios

7 years
Metric (FY)TTM202420232022202120202019
Price to Earnings (P/E)-23.3-39.53-0.38-0.16-1.96-2.53-79.24
Price to Book (P/B)10.328.430.290.351.24-1.850
Price to Sales (P/S)5.576.770.330.382.273.4112
Enterprise Value to EBITDA-34.49-1664.93-0.64-0.11-0.42-2.410
EV to Sales5.86.870.430.180.443.060
EV to Operating Cash Flow-54.12-73.62-0.48-0.13-0.49-5.880
EV to Free Cash Flow-34.78-61.72-0.47-0.13-0.44-4.380
Enterprise Value$2.64B$2.10B$86.95M$42.36M$92.46M$547.89M$0.00

WGS Historical Profitability Ratios

7 years
Metric (FY)TTM202420232022202120202019
Return on Equity (ROE)-38.72%-21.32%-77.09%-216.39%-63.23%73.12%0.00%
Return on Invested Capital (ROIC)-14.69%-6.21%-49.34%-171.43%-97.79%-131.89%0.00%
Return on Tangible Assets-31.42%-20.05%-58.38%-180.41%-44.29%-95.91%0.00%
Earnings Yield-4.22%-2.53%-262.90%-615.70%-50.91%-39.50%-1.26%
Free Cash Flow Yield-3.00%-1.64%-277.99%-374.00%-43.82%-20.48%-1.45%
Dividend Yield0.00%0.00%0.00%0.00%0.00%0.00%0.00%

WGS Historical Liquidity & Financial Strength

7 years
Metric (FY)TTM202420232022202120202019
Current Ratio3.33.613.11.474.772.370
Interest Coverage-20.31-7.660-208.19-157.37-97.81-38.84
Income Quality0.460.551.020.580.780.390.63
Debt to Equity0.690.470.530.30.03-0.140
Debt to Assets34.77%27.70%25.29%15.71%1.99%17.89%0.00%
Net Debt to EBITDA-1.4-24.57-0.150.121.760.280

WGS Historical Efficiency Ratios

7 years
Metric (FY)TTM202420232022202120202019
Receivables Turnover5.448.126.175.417.995.550
Payables Turnover28.0813.9610.995.685.126.560
Inventory Turnover8.1110.4312.8219.136.847.020
Days Sales Outstanding67.1644.9759.1367.4145.6965.810
Days Payables Outstanding1326.1433.264.2471.355.670
Days of Inventory on Hand453528.4619.0853.3751.980

WGS Historical Market Metrics

7 years
Metric (FY)TTM202420232022202120202019
Enterprise Value to EBITDA-34.49-1664.93-0.64-0.11-0.42-2.410
Market Cap$2.53B$2.07B$66.86M$89.16M$482.03M$610.99M$2.35B
Enterprise Value$2.64B$2.10B$86.95M$42.36M$92.46M$547.89M$0.00
Dividend Yield0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Payout Ratio0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Frequently Asked Questions

How does GeneDx Holdings Corp.’s P/E ratio compare with its history?

On this page, you can use the latest P/E (from the Key Ratios table) as your starting point and compare it to the company's multi-year P/E range in the historical rows. When the current P/E sits near its historical average, the multiple is close to that range. Look at trend direction in profitability and cash-flow rows, plus liquidity and leverage, rather than treating the P/E in isolation.

What is GeneDx Holdings Corp. market cap?

Market cap is the market value of a company's equity and is commonly calculated as share price multiplied by shares outstanding. The latest market cap shown in the table is $2.53B. Pair market cap with valuation multiples (P/E, P/B, P/S) so you can evaluate whether size also corresponds with "quality" and profitability. For a wider view across stocks, you can also use the stock screener.

How does GeneDx Holdings Corp.’s P/E compare with its industry?

There is no P/E Tickerplace rates as good. Compare the P/E on this page with GeneDx Holdings Corp.'s own historical range (in the table) and with peers via the Screener and Compare tools. A higher or lower multiple versus peers is a calculated gap, not a recommendation.

How does GeneDx Holdings Corp. compare to its competitors in key financial ratios?

The fastest way to compare GeneDx Holdings Corp. with competitors is to use the built-in "Peers Comparison" section on this page and the Compare tool. Focus on a small set of ratios that work together: P/E for valuation, ROE/ROIC for profitability and capital efficiency, current ratio and interest coverage for liquidity and solvency, and debt-to-equity for leverage risk. When you see GeneDx Holdings Corp. outperform peers on profitability while keeping valuation and leverage reasonable, it often signals stronger fundamentals.

What do GeneDx Holdings Corp.'s liquidity and leverage ratios show?

Liquidity and leverage figures on this page are published ratios, not a verdict that GeneDx Holdings Corp. is financially strong. Current ratio is about 3.30, which is above 1.0 and can indicate more comfortable short-term liquidity. Interest coverage is about -20.31, implying less buffer for servicing interest costs. Debt-to-equity is about 0.69, suggesting leverage is more moderate relative to a high-debt profile. Pair them with ROE/ROIC and cash-flow rows in the table. Tickerplace does not rate the company as a good or poor investment.

What do GeneDx Holdings Corp.'s financial ratios say about its future growth?

Ratios are a way to see what the business is likely to sustain. Look for upward trends in profitability metrics (ROE and ROIC), improving earnings/cash-flow backed measures, and stable or strengthening liquidity. If GeneDx Holdings Corp. is sustaining strong returns (for example ROE at -38.72% and ROIC at -14.69%) while debt levels and interest coverage remain manageable, growth expectations may be more credible. If valuation multiples expand while returns weaken, the market may be pricing optimistic growth ahead of results.